16 assets in Thrombotic Disease

Therapeutic assets addressing Thrombotic Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Rivaroxaban Thrombotic Disease	Shanghai Zhongshan Hospital	P4	BBB (76)
Aspirin Thrombotic Disease	China National Center for Cardiovascular Diseases	P4	BBB (73)
Apixaban Thrombotic Disease	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	P4	BB (71)
Dabigatran Thrombotic Disease	St. Antonius Hospital	P4	BB (69)
Warfarin Thrombotic Disease	China National Center for Cardiovascular Diseases	P4	BB (68)
Enoxaparin Thrombotic Disease	Helsinki University Central Hospital	P4	BB (66)
Clopidogrel Thrombotic Disease	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	P4	BB (65)
Edoxaban Thrombotic Disease	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	P4	BB (65)
Tenecteplase Thrombotic Disease	Mahidol University	P4	BB (65)
Tinzaparin Thrombotic Disease	Helsinki University Central Hospital	P4	BB (65)
Alteplase Thrombotic Disease	Second Affiliated Hospital, School of Medicine, Zhejiang University	P4	BB (64)
Recombinant Human Prourokinase For Thrombotic Disease	Beijing Tiantan Hospital	P3	BB (64)
Dalteparin Thrombotic Disease	Helsinki University Central Hospital	P4	B (62)
Human Immunoglobulins Thrombotic Disease	National Institute of Neurological Disorders and Stroke (NINDS)	P2	CCC (53)
Asundexian Thrombotic Disease	Bayer	P1	CC (47)
Atorvastatin Thrombotic Disease	Yang I. Pachankis	P1	NR ()